Halozyme Therapeutics | HALO - 资产



金融业
股票价格
USD
资产
USD 2.58B
现金及等价物
USD 163.14M
销售成本
USD 108.68M
流动资产
USD 933.02M
流动负债
USD 344.44M
债务
USD 2.14B
EBIT
USD -63.72M
EBITDA
USD 328.81M
员工
350
EPS每股收益
USD 2.28
股本和储备
USD 143.54M
销售毛利
USD 297.47M
债务利息支出
USD 5.59M
贷款资金
USD 1.94B
市值
USD 13.39B
净收入
USD 229.91M
营业费用
USD 193.35M
营业利润
USD -63.72M
普通股股本
USD 114.04M
PE价格收益
12.51
税前利润
USD 180.33M
销售收入
USD 481M
销售和管理费用
USD 57M
股票
USD 137.14M
贸易债权人
USD 23.61M
应收帐款人
USD 453.33M


资产 更改 日
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amarin USD 624.36M 21.4M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Baxter International USD 19.79B 55M 2026-06
Cara Therapeutics USD 25.82M 6.26M 2026-03
Cytokinetics USD 1.92B 651.07M 2026-06
DBV Technologies USD 223.2M 43.2M 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Halozyme Therapeutics USD 2.58B 95.31M 2026-06
Intrexon USD 73.16M 77.88M 2024-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
MannKind USD 732.3M 12.1M 2026-06
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Pfizer USD 201.13B 6.49B 2026-06
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
United Therapeutics USD 7.22B 505.9M 2026-06
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12